Project Grant R43GM154502
Award Date
7/1/24
Completion Date
6/30/25
Dollars Obligated
$694K
Federal Agency
National Institute of General Medical Sciences
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94107, USA
Similar Awards
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic kidney disease (DKD). Revel Pharmaceuticals Inc., a for-profit biotechnology company, received $648,030 to engineer enzymes that can efficiently cleave...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $108,793 to the University of Chicago to conduct structural and functional research on cadherin EGF laminin G seven-pass G-type receptors (CELSRs). The key objectives are to: 1) determine the structural basis for how the extracellular region of CELSRs regulates their cell adhesion and signaling functions, 2) test the...
This Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) provides $349,854 to Rezigene, LLC to develop an anti-proteotoxicity therapy for neurodegenerative diseases. The award will fund research investigating novel molecular targets identified through unbiased screening and testing new small molecule compounds designed to inhibit these targets. The goal is to expand the understanding of cellular defense systems against proteotoxic stress,...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $509,038 to Ceiba Bio Inc. to develop a blood-based exercise mimetic as a potential treatment for Alzheimer's disease and related dementias. The project aims to identify lead recombinant human GPLD1 molecules, conduct in vivo pharmacokinetic profiling, and test the disease-modifying effects of GPLD1 in an Alzheimer's mouse model. Successful completion of these aims is expected to advance the...
The National Institute of General Medical Sciences (NIGMS) awarded a $350,000 Project Grant (CFDA 93.859, Biomedical Research and Research Training) to GMJ Technologies, Inc., a minority-owned small disadvantaged business, to develop a high-resolution native capillary zone electrophoresis system with inline UV and native mass spectrometry capabilities. This innovative analytical technology is designed to enhance the characterization and quality control of protein therapeutics, such as monoclonal...
This Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) provides funding of $1,274,632.00 to Epicypher, Inc. to develop CUTANA-RH, a novel technology platform for genome-wide profiling of R-loops to accelerate aging and neurodegenerative disease research. The key innovations include a modular immunotethering strategy utilizing a catalytically inactive RNase H1 enzyme, as well as the development of designer nucleosome spike-in controls. Phase II of the project...
The U.S. National Institute on Aging (NIA) awarded a $472,695 Project Grant under the Aging Research federal grant program (CFDA 93.866) to 3D Bioanalytix, Inc., a woman-owned small business located in San Diego, CA. The grant supports the development of a blood-based diagnostic test for early detection and differentiation of neurodegenerative diseases such as Alzheimer's, Parkinson's, and related disorders. The project will leverage a novel Covalent Protein Painting (CPP) technology platform to...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training Program (CFDA 93.859), provides $299,978 to Lifesensors Inc. to develop novel molecular technologies for targeted protein degradation. The key focus is on creating innovative approaches to identify and design "molecular glue degraders" that can induce ubiquitination and subsequent proteasomal degradation of hard-to-drug proteins, with a...
The National Institute of General Medical Sciences (NIGMS) awarded a $947,705 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Applied Biophysics, Inc. of Troy, NY. The grant, spanning from July 2024 to June 2026, aims to develop an "Impedance-Based Cell Assurance Monitor (CAM)" instrument to assist researchers in detecting cell line misidentification, mycoplasma contamination, and subtle changes in cell populations during long-term culture....
The National Institute of General Medical Sciences (NIGMS) awarded a $358,862 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to GMJ Technologies, Inc., a minority-owned small business, to develop a microfluidic SDS depletion electrophoresis (SDE) interface. This interface will enable direct coupling of capillary electrophoresis with sodium dodecyl sulfate (CE-SDS) to mass spectrometry for improved characterization and quality control of monoclonal...